Literature DB >> 3395997

Cytogenetic characterization of an established xenografted prostatic adenocarcinoma cell line (PC-82).

J J König1, A Hagemeijer, B Smit, E Kamst, J C Romijn, F H Schröder.   

Abstract

Detailed cytogenetic analysis was performed of a xenografted human prostatic adenocarcinoma cell line PC-82. A direct preparation method was developed that yielded metaphases of good quality. Flow cytometric data and banding analysis of metaphases showed a near-tetraploid karyotype with 18 consistent marker chromosomes. As a result of the rearrangements involved, parts of chromosomes 2, 3, 4, 7, 9, 10, 15, 18, and 21 were homozygous, while regions on 2p, 13q, and 17q were apparently completely lost. In contrast to this, some regions on #2, #5, and, especially, on #1 were present in three or even four times the normal copy number. Comparison of affected chromosomes in PC-82 with all data available on prostatic carcinoma showed chromosomes 1, 2, 3, 6, 7, 10, and 15 to be involved in rearrangements in over 50% of all prostatic carcinomas. When only data from primary prostatic adenocarcinomas (including PC-82) were taken into account it appeared that chromosomes 1, 7, and 10 were involved in all five primary tumors studied.

Entities:  

Mesh:

Year:  1988        PMID: 3395997     DOI: 10.1016/0165-4608(88)90173-2

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Cytogenetic characterization of several androgen responsive and unresponsive sublines of the human prostatic carcinoma cell line LNCaP.

Authors:  J J König; E Kamst; A Hagemeijer; J C Romijn; J Horoszewicz; F H Schröder
Journal:  Urol Res       Date:  1989

2.  Allelic loss of chromosomes 16q and 10q in human prostate cancer.

Authors:  B S Carter; C M Ewing; W S Ward; B F Treiger; T W Aalders; J A Schalken; J I Epstein; W B Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

Review 3.  Serially heterotransplanted human prostate tumours as an experimental model.

Authors:  Lluis-A Lopez-Barcons
Journal:  J Cell Mol Med       Date:  2009-10-29       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.